Immunomedics, Inc.
IMMU, a biopharmaceutical company primarily focused on the
development of monoclonal antibody-based products for the targeted treatment
of cancer, autoimmune and other serious diseases, today announced that it has
received notice that its patent application for "Anti-CD19 antibodies," will
issue as US patent No. 8,337,840 on December 25, 2012.
The allowed claims under the patent cover the use of specific humanized
anti-CD19 monoclonal antibodies and fragments thereof for the treatment of
autoimmune diseases. The antibodies and fragments thereof can be used alone,
conjugated to at least one therapeutic agent or in combination with other
humanized, chimeric, human or murine monoclonal antibodies, such as antibodies
reactive with CD20, CD22, CD74 or HLA-DR.
This patent, which provides coverage until 2024, also protects (19)-3s, a
novel T-cell redirecting agent made as a DOCK-AND-LOCK™ (DNL™) complex using
the Company's patented platform technology. The DNL™ complex recognizes CD19
on B cells and binds to CD3 on T cells. At the 2012 Annual Meeting of the
American Society of Hematology, (19)-3s was reported to bind to T cells and
non-Hodgkin lymphoma (NHL) cells simultaneously, and induce T-cell-mediated
killing of NHL cells at less than 1 picomolar (pM) concentrations in an ex
vivo setting, with maximal activity at 10 pM. (For more information, please
refer to the Company's press release at
www.immunomedics.com/pdfs/news/2012/pr12122012.pdf).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in